Driving the Next Generation of In Vivo Therapies
VIVEbiotech ensures pharmaceutical grade quality and expert support for programs already advancing into the clinic.
The momentum around in vivo lentiviral vectors continues to rise, and VIVEbiotech is proud to be at the forefront of this rapidly evolving field. As more therapeutic programs incorporate in vivo administration, ensuring the highest analytical and regulatory standards has become more crucial than ever.
In a new video, Marisa Molina, Head of Quality Control, highlights how the QC team at VIVEbiotech is supporting this growth with solid expertise and a firm commitment to quality. With 12 in vivo programs currently supported, including several already in clinical stages, VIVEbiotech has developed a deep understanding of the technical, analytical, and regulatory expectations unique to vectors intended for direct patient administration.
Our approach includes strict alignment with FDA and EMA guidelines, expanded analytical characterization, and the ability to develop and validate new QC assays on demand to meet the needs of each program. This combination of scientific rigor and flexibility allows us to provide robust, pharmaceutical‑grade support throughout the development process.
At VIVEbiotech, our mission remains clear: to help advance innovative therapies safely and effectively, ensuring that every vector we release meets the highest standards for patient safety and regulatory compliance.